AlzProtect SAS
Biopharmaceutical company developing small-molecule therapeutic candidates for neurodegenerative diseases, with a focus on tauopathies (Progressive Supranuclear Palsy) and Alzheimer’s disease. Activities span discovery, preclinical validation, GLP toxicology, and early- to mid-stage clinical development, with academic and clinical partnerships and regulatory interactions in Europe and the United States.
Industries
Nr. of Employees
small (1-50)
AlzProtect SAS
Patents
Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US-10772884-B2
View DetailsSulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US-10537569-B2
View DetailsSulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US-9562018-B2
View Details
Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US-10772884-B2
View DetailsSulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US-10537569-B2
View DetailsSulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US-9562018-B2
View DetailsProducts
AZP2006 (ezeprogind)
Orally administered small-molecule therapeutic candidate developed to modulate lysosomal function and progranulin-related pathways, investigated for tauopathies and other neurodegenerative diseases.
AZP2006 (ezeprogind)
Orally administered small-molecule therapeutic candidate developed to modulate lysosomal function and progranulin-related pathways, investigated for tauopathies and other neurodegenerative diseases.
Services
Discovery, medicinal chemistry and preclinical efficacy/safety studies for small-molecule candidates targeting neurodegenerative mechanisms.
Design and conduct of early-phase clinical studies (Phase I and Phase IIa), biomarker collection and analysis, and coordination of clinical sites and open-label extensions.
Discovery, medicinal chemistry and preclinical efficacy/safety studies for small-molecule candidates targeting neurodegenerative mechanisms.
Design and conduct of early-phase clinical studies (Phase I and Phase IIa), biomarker collection and analysis, and coordination of clinical sites and open-label extensions.
Expertise Areas
- Tauopathies research
- Small-molecule therapeutics
- Preclinical translational research
- Early-phase clinical development
Key Technologies
- Small-molecule drug discovery
- Rodent tauopathy models (e.g., Thy-Tau22)
- GLP toxicology studies
- Pharmacokinetic (PK) assessment
News & Updates
Company's therapeutic candidate was selected as one of the first two regimens to be evaluated in the PSP Trial Platform (PTP).
Announcement of the completion of a Phase 2a clinical trial evaluating the platform asset AZP2006 in Progressive Supranuclear Palsy, with reported tolerability and safety endpoints met.
Reported favorable feedback from both FDA and EMA on the regulatory path for advancing clinical development of the lead candidate toward Phase 2b/3.
Award of a grant (USD 338,000) to support preclinical development of the lead candidate in Parkinson’s disease models focused on progranulin and GBA1-related pathology.
Company's therapeutic candidate was selected as one of the first two regimens to be evaluated in the PSP Trial Platform (PTP).
Announcement of the completion of a Phase 2a clinical trial evaluating the platform asset AZP2006 in Progressive Supranuclear Palsy, with reported tolerability and safety endpoints met.
Reported favorable feedback from both FDA and EMA on the regulatory path for advancing clinical development of the lead candidate toward Phase 2b/3.
Award of a grant (USD 338,000) to support preclinical development of the lead candidate in Parkinson’s disease models focused on progranulin and GBA1-related pathology.